101.51
0.57%
-0.58
Overview
News
Price History
Option Chain
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc. stock is currently priced at $101.51, with a 24-hour trading volume of 808.12K.
It has seen a -0.57% decreased in the last 24 hours and a -1.85% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $102.1 pivot point. If it approaches the $101.0 support level, significant changes may occur.
Previous Close:
$102.09
Open:
$101.92
24h Volume:
808.12K
Market Cap:
$12.54B
Revenue:
$2.75B
Net Income/Loss:
$693.09M
P/E Ratio:
17.07
EPS:
5.9463
Net Cash Flow:
$9.90M
1W Performance:
+0.64%
1M Performance:
-1.85%
6M Performance:
+2.59%
1Y Performance:
+0.00%
Revvity Inc. Stock (RVTY) Company Profile
Name
Revvity Inc.
Sector
Industry
Phone
781 663 6900
Address
940 Winter Street, Waltham
Revvity Inc. Stock (RVTY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-16-24 | Downgrade | UBS | Buy → Neutral |
Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
Sep-28-23 | Initiated | Bernstein | Outperform |
Jul-19-23 | Initiated | Raymond James | Outperform |
May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc. Stock (RVTY) Latest News
Revvity's (RVTY) New Launch to Boost Tuberculosis Testing
Zacks Investment Research
Revvity's (RVTY) Launch to Boost Pharma-Contract Partner Tie-Up
Zacks Investment Research
Revvity (RVTY) Stock Jumps 4.1%: Will It Continue to Soar?
Zacks Investment Research
Three Reasons to Retain Revvity (RVTY) Stock in Your Portfolio
Zacks Investment Research
Revvity's (RVTY) New Launch to Boost Research Productivity
Zacks Investment Research
Revvity's (RVTY) New Launch to Boost Newborn Sequencing Research
Zacks Investment Research
Revvity Inc. Stock (RVTY) Financials Data
Revvity Inc. (RVTY) Revenue 2024
RVTY reported a revenue (TTM) of $2.75 billion for the quarter ending December 31, 2023, a -16.95% decline year-over-year.
Revvity Inc. (RVTY) Net Income 2024
RVTY net income (TTM) was $693.09 million for the quarter ending December 31, 2023, a +21.77% increase year-over-year.
Revvity Inc. (RVTY) Cash Flow 2024
RVTY recorded a free cash flow (TTM) of $9.90 million for the quarter ending December 31, 2023, a -98.33% decrease year-over-year.
Revvity Inc. (RVTY) Earnings per Share 2024
RVTY earnings per share (TTM) was $5.4965 for the quarter ending December 31, 2023, a +20.02% growth year-over-year.
Revvity Inc. Stock (RVTY) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
MICHAS ALEXIS P | Director |
Feb 29 '24 |
Sale |
109.98 |
5,000 |
549,900 |
55,604 |
Vohra Tajinder S | Please See Remarks |
Feb 27 '24 |
Option Exercise |
54.56 |
7,918 |
432,046 |
34,031 |
Vohra Tajinder S | Please See Remarks |
Feb 27 '24 |
Sale |
105.39 |
7,918 |
834,441 |
26,113 |
Singh Prahlad R. | Please See Remarks |
Feb 23 '24 |
Sale |
105.13 |
1,144 |
120,269 |
102,270 |
Goldberg Joel S | Please See Remarks |
Feb 23 '24 |
Sale |
105.13 |
835 |
87,784 |
40,900 |
Singh Prahlad R. | Please See Remarks |
Feb 05 '24 |
Option Exercise |
76.83 |
57,039 |
4,382,283 |
118,838 |
Goldberg Joel S | Please See Remarks |
Feb 05 '24 |
Option Exercise |
64.18 |
28,907 |
1,855,347 |
53,500 |
Vohra Tajinder S | Please See Remarks |
Feb 05 '24 |
Option Exercise |
105.62 |
3,554 |
375,373 |
27,359 |
Tereau Daniel R | Please See Remarks |
Feb 05 '24 |
Option Exercise |
105.62 |
2,835 |
299,433 |
14,446 |
Victor Miriame | Please See Remarks |
Feb 05 '24 |
Option Exercise |
105.62 |
2,408 |
254,333 |
11,500 |
About Revvity Inc.
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Cap:
|
Volume (24h):